GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Parmax Pharma Ltd

Parmax Pharma Board Approves Rs. 19.28 Crore Preferential Issue

FUNDRAISE ▲ Positive Development MEDIUM RISK
📅 Filed on BSE: 08 Jun 2026, 03:22 PM IST  ·  BSE ID: 14cd2156-70ca-4814-a91f-2103e93e5e2d
View Original BSE Filing (PDF)
💡
In Simple Terms
The company's board plans to sell new shares and warrants to raise money and boost its authorized capital.
🤖 AI Summary
  • Board approved raising up to Rs. 19,28,19,682 via preferential issue.
  • Issue comprises equity shares and convertible warrants to non-promoter group.
  • Authorized capital increased from Rs. 6,00,00,000 to Rs. 10,00,00,000.
  • New Articles of Association to be adopted, subject to shareholder approval.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Total fundraising via preferential issue
Rs. 19,28,19,682
Increase in Authorized Capital
Rs. 10,00,00,000
Existing Authorized Capital
Rs. 6,00,00,000
Number of equity shares to be issued
31,37,586
Issue price per equity share
Rs. 36.50
Number of convertible warrants to be issued
21,45,145
Issue price per warrant
Rs. 36.50
🏢 How This Affects the Company
📈
Business Impact
This preferential issue is intended to strengthen the company's financial position to support its business operations and growth initiatives.
💰
Financial Impact
The issuance of shares and warrants will infuse capital into the company, increasing its cash reserves and equity base, subject to shareholder approval.
⚠️
Risk Impact
The company will seek shareholder approval for this preferential issue, introducing a regulatory approval risk until the transaction is finalized.
👥 What This Means For Shareholders
✅
Action Required
Shareholders will need to vote on the preferential issue and the proposed changes to the Memorandum and Articles of Association.
👤
Who Is Affected
All shareholders are affected by the potential dilution from the preferential issue and the increase in authorized capital.
🔍
Management Signal
Management is actively pursuing capital raising and restructuring of the company's capital structure to facilitate future growth.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Shareholder meeting for approval of preferential issue.
Regulatory filings for preferential issue completion.
Company announcement on utilization of funds raised.
MEDIUM RISK Fundraising is subject to shareholder and regulatory approvals, with potential dilution for existing shareholders.
💡 Investor Takeaway
Parmax Pharma's Board approved raising up to Rs. 19,28,19,682 via preferential issue of shares and warrants to non-promoter category. Authorized capital is increased from Rs. 6 Crore to Rs. 10 Crore.
⚖️ Strengths & Concerns

✅ Positives

  • Board approved a total fundraising of Rs. 19,28,19,682 through preferential issue.
  • Authorized share capital increased by Rs. 4,00,00,000, from Rs. 6 Crore to Rs. 10 Crore.

⚠️ Concerns

  • Fundraising is subject to shareholder and regulatory approvals, introducing execution risk.
  • The preferential issue price of Rs. 36.50 per share/warrant is determined by SEBI ICDR regulations.
❓ Frequently Asked Questions
What is the total amount Parmax Pharma plans to raise through its preferential issue?
Parmax Pharma plans to raise up to Rs. 19,28,19,682 (Rupees Nineteen crores twenty-eight lakhs nineteen thousand six hundred and eighty-two) through the preferential issue.
What is the new authorized share capital of Parmax Pharma?
Parmax Pharma's authorized share capital has been increased to Rs. 10,00,00,000 (Rupees Ten Crore Only) from Rs. 6,00,00,000 (Rupees Six Crores).
How many equity shares will be issued in the preferential issue?
The company will issue 31,37,586 (Thirty-one lakhs thirty-seven thousand five hundred eighty-six) equity shares as part of the preferential issue.
What is the issue price for the equity shares and warrants in the preferential issue?
The issue price for both equity shares and convertible warrants is Rs. 36.50 (Rupees Thirty-six point five zero) per instrument.
Who are the proposed allottees for the preferential issue?
The securities will be issued to individuals belonging to the Non-Promoter Group category.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.